All Episodes

Outlook Wins Appeal for Wet AMD Drug Candidate Lytenava

Next-Generation FSYX Goggles Approved for Glaucoma

Future of Posterior Therapeutics

Bayer Acquires Perfuse in $2.45 Billion Deal

How Ophthalmology Strategics are Rewriting the Playbook

Glaukos Issued J-Code for Recently Launched Epioxa

Breaking News from the ASCRS Meeting in Washington DC

More than 3 Million Bottles of Eye Drops Recalled

Biogen Enters GA Treatment Market After Major Acquisition

Interview with ASCRS Executive Director Steve Speares

Alcon and Lensar Call Off Merger

FDA Agrees to Review Phentolamine for Presbyopia

Zeiss Launches App to Improve Workflow

Ocular Releases Phase 3 Data for Wet AMD Candidate Axpaxli

Study: Metformin May Lower AMD Progression

First Dual-Agent Eye Drop for Presbyopia Approved

FDA Approves Label Supplement for iDose TR

Rayner Launches New Phaco System

Moorfields Researchers Reveal Promising Treatment for Hypotony

Staar Terminates Merger with Alcon

2025 Year in Review - Part 2

2025 Year in Review - Part 1

Update on Reproxalap PDUFA Timing

New Glaucoma Technologies Advance in Clinical Development

Eylea HD Approved for RVO and Extended Dosing

Leaders Discuss Emerging Technologies in Glaucoma

Live Coverage of B+L Investor Day

Ryjunea Approved in the UK for Myopia

Ophthalmic Executives Provide Company Updates (Part 2 of 2)

Ophthalmic Executives Provide Company Updates (Part 1 of 2)

Breaking News from the AAO Meeting in Orlando

First Robotic Cataract Surgery Performed

Lenz Therapeutics' Vizz Commerically Launched

Visionary Breakthroughs: A Spotlight on Innovations in Eye Care (Part 2 of 2)

Visionary Breakthroughs: A Spotlight on Innovations in Eye Care (Part 1 of 2)

Breaking News From the ESCRS Congress in Copenhagen

Vision Advocacy Leaders Speak Out Against Proposed NEI Cuts

Update on Investigational Treatments for Retinal Diseases

CE Certification for New Glaucoma Surgical Implant

Special Report: TFOS DEWS III Leaders Discuss New DED Guidance

First Commerical Surgeries Performed with MacTel Therapy

Alcon Acquires Staar for $1.5 Billion

Tryptyr Now Available in US

Harrow Adds Biosimilars to US Portfolio

AECOS Presentation Summaries

Alcon Acquires LumiThera

Glaukos' MIGS Technology Certified in Europe; New Phase 3 Data for Presbyopia Drop

Special Report: Update on Holland Foundation

TFOS DEWS III Published

First Myopia Drug Approved in Europe

Alcon Gains FDA Approval for Novel DED Drug

Special Report: Executives Discuss Overcoming Challenges

B+L Launches New Scleral Lenses Technology

B+L Receives Approval in Europe for LuxLife IOL

Ophthalmic Leaders Launch SightLine Meeting

Breaking News from the ASCRS Meeting in Los Angeles

FDA Issues CRL to Regeneron for Eylea HD Extended Dosing

Orasis Launches Presbyopia Eye Drop Qlosi

Utilizing AI to Provide DR Screening to Underserved Communities

Alcon Launches PanOptix Pro in US

Alcon Announces Plans to Acquire Lensar

FDA Expands Product Label for Iluvien

FDA Approves First Treatment for MacTel

Haag-Streit Launches METIS 900 Microscope

New Myopia Software on Pentacam AXL

Alcon Voyager DSLT Fully Launched in US

AAO Opposes NIH Research Funding Proposal

FDA Approves Genentech's Susvimo Ocular Implant for DME

Norlase Launches First Pattern Scanning LIO

Zeiss MEL 90 Approved by FDA

Special Report – Increasing Access to Care Through the Cure Blindness Project

Glaukos Submits NDA for Epi-On CLX Candidate

2024 Year in Review — Part 2

2024 Year in Review — Part 1

B+L Bolsters Glaucoma Offerings with Elios Acquisition

Phase 3 Results for Novel Sedation Tablet

Phakic IOL for Presbyopia Approved in Europe

Special Report: OWL Celebrates 20th Anniversary

Lumithera CEO Discusses FDA Authorization for Veleda for Dry AMD

Ophthalmic Executives Provide Company Updates (Part 2 of 2)

Ophthalmic Executives Provide Company Updates (Part 1 of 2)

Posterior Segment Company Updates

Breaking News From the AAO Meeting in Chicago

B+L Receives FDA Approval for enVista Envy IOL

Aldeyra Resubmits NDA for DED Drug Reproxalap

Water-Free Ciclosporin-Based Eye Drop for DED Approved in Europe

Two Partnerships Formed to Advance Glaucoma Treatments

Breaking News From the ESCRS Congress in Barcelona (Part 2 of 2)

Breaking News From the ESCRS Congress in Barcelona (Part 1 of 2)

Weekly Headlines: First Therapy for Acanthamoeba Keratitis Approved in Europe

Weekly Headlines: Rayner Unveils First AI-Designed Spiral IOL

Weekly Headlines: Gene Therapies for IRDs Receive FDA Rare Pediatric Disease Designations

Weekly Headlines: Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap

Weekly Headlines: Two Phase 3 Trials for Dry and Wet AMD Drug Candidates Begin